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LETTERS TO THE EDITOR
Regarding “Protected carotid stenting in
high-surgical-risk patients: The ARCHeR results”
Although the authors are to be commended upon being the
only one of the 10 or so “high-risk” stent registries to publish
their results in a peer-reviewed journal,1 ARCHeR (as with
SAPPHIRE2) raises more questions than it answers.
Two important issues warrant attention. The first is the statis-
tical appropriateness of performing a noninferiority analysis on
nonrandomized data. Noninferiority studies (eg, is angioplasty as
good as endarterectomy) are relatively uncommon in contempo-
rary surgical practice, unlike equivalence or superiority studies.
Trial methodology requires the investigator to specify a noninferi-
ority margin before the trial starts (in this case, 4%). The two
treatment modalities are then (usually) compared in a prospective
randomized trial so that variables are matched and there is less
chance for unwanted bias. In ARCHeR, historic surgical outcome
data were used, and this will inevitably raise concerns about bias
and generalizability, as was noted by Bill Mackey in his commen-
tary. Moreover, although the authors apparently defined their
noninferiority margin before ARCHeR 1 started recruiting, it is
hard to see how this could remain statistically valid, for a number of
reasons. First, the “hypothesis (page 259) was constructed statis-
tically to assess whether the 1-year composite primary endpoint
(anticipated at 10% for stenting) was within an acceptable margin
of the historical control rate (14.4%).” This implies that the
historic control of 14.4% was defined from the outset (ie, good trial
practice). It is, therefore, hard to reconcile this statement with the
subsequent observation (page 260) that “at the completion of the
study, the proportion of actual enrollment in these two broad
categories was calculated and the final 1-year endpoint comparator
was estimated at 14.4%.” Second, three sequential studies were
undertaken (one of which did not complete enrollment), each
with a different power (ARCHeR 1, 80%; ARCHeR 2, 90%; and
ARCHeR 3, 85%) and each with a very heterogeneous cohort of
symptomatic and asymptomatic patients. To this reader, it seemed
inappropriate that the noninferiority margin of 4% was applied
equally to both symptomatic and asymptomatic patients.
The second area of concern is how the conclusions should be
applied to mainstream clinical practice. The Figure presents a
reanalysis of how the 30-day operative risk influences stroke pre-
vention. These data were derived from a reanalysis of outcomes
from the Carotid Endarterectomy Trialists Collaboration, which
combined data from 6000 recently symptomatic patients with 50%
to 99% stenoses randomized into the European Carotid Surgey
Trial (ECST), the North American Symptomatic Carotid Endar-
terectomy Trial (NASCET) and the Veterans Administration (VA)
Study studies and in whom all the prerandomization angiograms
were remeasured by using the NASCET method.3 Parallel data for
asymptomatic patients were derived from a reworking of the
Asymptomatic Carotid Atherosclerosis Study results.4
In asymptomatic patients (76% of the ARCHeR cohort), the
presence of recurrent laryngeal nerve palsy, unstable angina, and
pulmonary disease did not increase the long-term risk of stroke.5
Accordingly, there is no evidence that morbidity/mortality thresh-
olds should be changed from the recommended 3% level. The
30-day death/stroke risk in asymptomatic patients in ARCHeR
was 5.4%—well in excess of accepted guidelines. At this level of
risk, only 29 strokes will be prevented at 5 years by performing
1000 angioplasty procedures (ie, there will be 971 unnecessary
interventions). Accordingly, the recommendation should probably
remain that provided that the procedural risk is 3% or less, angio-
plasty does have a role in high-risk asymptomatic patients. Con-
versely, most surgeons would accept that symptomatic patients
face a much higher long-term stroke risk (ie, it would be reasonable
to increase the threshold in selected high-risk individuals). How-
ever, few would thereafter accept that a greater than 11% 30-day
risk justifies recommending angioplasty in all symptomatic patients
who are otherwise considered high-risk for surgery.
ARCHeR concluded that “carotid stenting is a safe, durable
and effective alternative in high-surgical risk patients.” To
qualify as being high-risk, the patient really does have to be
symptomatic, and it is debatable whether a procedural risk of
more than 11% in symptomatic patients justifies this conclusion.
Similarly, with a more than 5% procedural risk in asymptomatic
patients, it is hard not to conclude from ARCHeR (as with
SAPPHIRE) that few (if any) of these high-risk asymptomatic
individuals required any intervention at all (Fig 1).
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Fig 1. Number of strokes prevented at 5 years by performing 1000
carotid endarterectomies stratified for 30-day operative risk. Symp-
tomatic data were derived from the Carotid Endarterectomy Trialists
Collaboration (CETC), which pooled data from 6000 symptomatic
patients with 50% to 99% stenoses from the European Carotid Sur-
gery Trial, North American Symptomatic Carotid Endarterectomy
Trial, and Veterans Administration study.3 Asymptomatic data were
derived from asymptomatic patients with 60% to 99% stenoses in the
Asymptomatic Carotid Atherosclerosis Study (ACAS).4
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Reply
We appreciate the commentary provided by Dr Mackey and
Professor Naylor on the ARCHeR publication and the opportunity
to respond.
Professor Naylor commends us on “being the only one of the
10 or so ‘high-risk’ [sic] stent registries to publish” results, and
although we appreciate the salute, we refer Professor Naylor to the
publication of the CREATE trial by Safian et al1 several months
ago, and we know of at least one other study currently in review. As
a point of clarification, there have been seven high-surgical-risk
registries completed in the United States since the advent of
embolic protection devices.
Two specific issues are raised by Professor Naylor, one con-
cerning statistical methodology and the other the clinical applica-
bility of results. Regarding methodology, the noninferiority design
is increasingly common where the intent is to establish a reasonable
technology or technique alternative to an existing therapy (which
may be preferred because of less invasiveness or cost, greater
availability, and so on) and where previous literature exists to
establish a control rate.2 In addition, noninferiority trial designs are
generally preferred over equivalence trials, which are unnecessarily
two tailed. In the case of carotid stenting in the United States,
randomization in high-surgical-risk trials was believed to likely
hinder timely enrollment (as evidenced by the SAPPHIRE trial),
so this alternative study design was established.
Both Professor Naylor and Dr Mackey question various com-
ponents of and/or methods used for the comparator—specifically,
the weighted historical control. This information was not included
in our original article because of space constraints. To be clear, the
methodology for the determination of a weighted historical con-
trol was established a priori in a binding contract with the Food
and Drug Administration before the first patient was enrolled in
ARCHeR. Once the last patient was enrolled, the 14.4% compar-
ator was computed from the prespecified 1-year composite end
point rates, which were 15% for comorbid conditions and 11% for
anatomic conditions, and weighted according to the actual distri-
bution in those categories. Although we appreciate Professor
Naylor’s concern with stopped trials,3 as explained in the text of
the article, ARCHeR 1 was rolled over into ARCHeR 2 to allow for
the introduction of the embolic protection filter and not for clinical
or outcome reasons; it did not complete enrollment by agreement
with the overseeing regulatory body. Moreover, all three phases of
the trial were conducted with the same inclusion and exclusion
criteria, which resulted not only in their poolability, but also in a
homogeneous distribution of symptomatic patients across three trials.
Both Professor Naylor and Dr Mackey go to great lengths
to prove that the concept of a high-surgical-risk patient is a
fallacy. It is unfortunate that leaders in the field in vascular surgery
continue to beat this drum, providing in support only retrospective
data from single surgeons or centers, all of which lack both
rigorous neurologic audit and 30-day follow-up, which have be-
come the standard for assessing carotid stent procedural outcomes.
Previous studies have clearly demonstrated a threefold increase in
apparent stroke rates with prospective neurologic evaluation, as
was performed in ARCHeR.4,5 What is not offered is the contem-
porary outcomes in a very similar endarterectomy cohort in the
SAPPHIRE trial,6 in which the 1-year composite end point in the
surgical group was 20.1% and higher than the randomized stent
cohort at every time point.
More recently, the generalizability of these results in the nontrial
setting has been demonstrated in the subsequent CAPTURE registry
(TCT 2006 Scientific Sessions, oral presentation. October 2006),
in which the 30-day rates of adverse outcomes in more than 3500
patients tracked with neurologic audit are lower than these AR-
CHeR results. In contrast, real-world mortality rates with carotid
endarterectomy have been reported to be nearly three times higher
than those in landmark clinical trials.7
Any attempt to compare data from the ARCHeR trials with a
normal-surgical-risk historical cohort will be missing the point.
High-surgical-risk patients not only are at increased risk for end-
arterectomy, but are also likely to be at increased risk for stroke as
well. Data from the Asymptomatic Carotid Stenosis and Risk of
Stroke group confirm that the existence of even two comorbid
factors (contralateral transient ischemic attack and renal insuffi-
ciency) are associated with an increase in the 1-year event rate from
2.3% to 7.3% in patients with carotid disease.8
The field of vascular surgery has had more than 50 years of
experience with endarterectomy, yet it has failed to conduct a
single study vs medical therapy among high-surgical-risk candi-
dates. Nonetheless, large numbers of individuals at high surgical
risk undergo endarterectomy each year. It seems, then, somewhat
disingenuous to suggest that carotid stenting, which compares
favorably to surgery in this population, should be discarded as a
therapeutic option because it has not proven any effectiveness vs
medical therapy. We nonetheless agree with Dr Mackey that fur-
ther study of these two therapies with both prospective neurologic
evaluation and long-term follow-up will help define the need for,
and utility of, carotid revascularization in this population.
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